The approved treatments available for AD are limited to symptomatic management and consist mostly of acetylcholinesterase inhibitors (AChE) and N‐methyl‐D‐aspartate (NMDA) receptor antagonist, palliatives agents that alleviate the cognitive and functional deficits for a limited time 8. Here, ACHE is linked to Alzheimer disease.